当前位置: 首页 >> 检索结果
2481. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
作者: Roser Pinyol.;Robert Montal.;Laia Bassaganyas.;Daniela Sia.;Tadatoshi Takayama.;Gar-Yang Chau.;Vincenzo Mazzaferro.;Sasan Roayaie.;Han Chu Lee.;Norihiro Kokudo.;Zhongyang Zhang.;Sara Torrecilla.;Agrin Moeini.;Leonardo Rodriguez-Carunchio.;Edward Gane.;Chris Verslype.;Adina Emilia Croitoru.;Umberto Cillo.;Manuel de la Mata.;Luigi Lupo.;Simone Strasser.;Joong-Won Park.;Jordi Camps.;Manel Solé.;Swan N Thung.;Augusto Villanueva.;Carol Pena.;Gerold Meinhardt.;Jordi Bruix.;Josep M Llovet.
来源: Gut. 2019年68卷6期1065-1075页
Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma (HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70% 5-year recurrence rates. The phase 3 STORM trial comparing sorafenib with placebo as adjuvant treatment did not achieve its primary endpoint of improving recurrence-free survival (RFS). The biomarker companion study BIOSTORM aims to define (A) predictors of recurrence prevention with sorafenib and (B) prognostic factors with B level of evidence.
2484. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.
作者: Vipul Jairath.;Laurent Peyrin-Biroulet.;Guangyong Zou.;Mahmoud Mosli.;Niels Vande Casteele.;Reetesh K Pai.;Mark A Valasek.;Aude Marchal-Bressenot.;Larry W Stitt.;Lisa M Shackelton.;Reena Khanna.;Geert R D'Haens.;William J Sandborn.;Allan Olson.;Brian G Feagan.;Rish K Pai.
来源: Gut. 2019年68卷7期1162-1168页
We evaluated the reliability and responsiveness of available but incompletely validated UC histological disease activity indices using standardised rules for centralised assessment.
2486. Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.
作者: Pavel Strnad.;Stephan Buch.;Karim Hamesch.;Janett Fischer.;Jonas Rosendahl.;Renate Schmelz.;Stefan Brueckner.;Mario Brosch.;Carolin V Heimes.;Vivien Woditsch.;David Scholten.;Hans Dieter Nischalke.;Sabina Janciauskiene.;Mattias Mandorfer.;Michael Trauner.;Michael J Way.;Andrew McQuillin.;Matthias C Reichert.;Marcin Krawczyk.;Markus Casper.;Frank Lammert.;Felix Braun.;Witigo von Schönfels.;Sebastian Hinz.;Greta Burmeister.;Claus Hellerbrand.;Andreas Teufel.;Alexandra Feldman.;Joern M Schattenberg.;Heike Bantel.;Anita Pathil.;Muenevver Demir.;Johannes Kluwe.;Tobias Boettler.;Monika Ridinger.;Norbert Wodarz.;Michael Soyka.;Marcella Rietschel.;Falk Kiefer.;Thomas Weber.;Silke Marhenke.;Arndt Vogel.;Holger Hinrichsen.;Ali Canbay.;Martin Schlattjan.;Katharina Sosnowsky.;Christoph Sarrazin.;Johann von Felden.;Andreas Geier.;Pierre Deltenre.;Bence Sipos.;Clemens Schafmayer.;Michael Nothnagel.;Elmar Aigner.;Christian Datz.;Felix Stickel.;Marsha Yvonne Morgan.;Jochen Hampe.;Thomas Berg.;Christian Trautwein.
来源: Gut. 2019年68卷6期1099-1107页
Homozygous alpha1-antitrypsin (AAT) deficiency increases the risk for developing cirrhosis, whereas the relevance of heterozygous carriage remains unclear. Hence, we evaluated the impact of the two most relevant AAT variants ('Pi*Z' and 'Pi*S'), present in up to 10% of Caucasians, on subjects with non-alcoholic fatty liver disease (NAFLD) or alcohol misuse.
2488. Treatment with camu camu (Myrciaria dubia) prevents obesity by altering the gut microbiota and increasing energy expenditure in diet-induced obese mice.
作者: Fernando F Anhê.;Renato T Nachbar.;Thibault V Varin.;Jocelyn Trottier.;Stéphanie Dudonné.;Mélanie Le Barz.;Perrine Feutry.;Geneviève Pilon.;Olivier Barbier.;Yves Desjardins.;Denis Roy.;André Marette.
来源: Gut. 2019年68卷3期453-464页
The consumption of fruits is strongly associated with better health and higher bacterial diversity in the gut microbiota (GM). Camu camu (Myrciaria dubia) is an Amazonian fruit with a unique phytochemical profile, strong antioxidant potential and purported anti-inflammatory potential.
2489. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study.
作者: Louise Jm Alferink.;Jessica C Kiefte-de Jong.;Nicole S Erler.;Bart J Veldt.;Josje D Schoufour.;Robert J de Knegt.;M Arfan Ikram.;Herold J Metselaar.;Harry LA Janssen.;Oscar H Franco.;Sarwa Darwish Murad.
来源: Gut. 2019年68卷6期1088-1098页
A healthy lifestyle is the first-line treatment in non-alcoholic fatty liver disease (NAFLD), but specific dietary recommendations are lacking. Therefore, we aimed to determine whether dietary macronutrient composition is associated with NAFLD.
2490. Periendoscopic management of direct oral anticoagulants: a prospective cohort study.
作者: Franco Radaelli.;Lorenzo Fuccio.;Silvia Paggi.;Cesare Hassan.;Alessandro Repici.;Emanuele Rondonotti.;Rossella Semeraro.;Milena Di Leo.;Andrea Anderloni.;Arnaldo Amato.;Cristina Trovato.;Ivana Bravi.;Andrea Buda.;Mario de Bellis.;Valentina D'Angelo.;Sergio Segato.;Ottaviano Tarantino.;Alessandro Musso.;Renato Fasoli.;Leonardo Frazzoni.;Elisa Liverani.;Carlo Fabbri.;Emilio Di Giulio.;Gianluca Esposito.;Flavia Pigò.;Andrea Iannone.;Francesco Dentali.; .
来源: Gut. 2019年68卷6期969-976页
To assess the frequency of adverse events associated with periendoscopic management of direct oral anticoagulants (DOACs) in patients undergoing elective GI endoscopy and the efficacy and safety of the British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) recommendations (NCT02734316).
2492. What's in a name? 'Non-coeliac gluten or wheat sensitivity': controversies and mechanisms related to wheat and gluten causing gastrointestinal symptoms or disease.
作者: Michael D E Potter.;Marjorie M Walker.;Simon Keely.;Nicholas J Talley.
来源: Gut. 2018年67卷12期2073-2077页 2494. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
作者: Zhigang Ren.;Ang Li.;Jianwen Jiang.;Lin Zhou.;Zujiang Yu.;Haifeng Lu.;Haiyang Xie.;Xiaolong Chen.;Li Shao.;Ruiqing Zhang.;Shaoyan Xu.;Hua Zhang.;Guangying Cui.;Xinhua Chen.;Ranran Sun.;Hao Wen.;Jan P Lerut.;Quancheng Kan.;Lanjuan Li.;Shusen Zheng.
来源: Gut. 2019年68卷6期1014-1023页
To characterise gut microbiome in patients with hepatocellular carcinoma (HCC) and evaluate the potential of microbiome as non-invasive biomarkers for HCC.
2495. Human CPA1 mutation causes digestive enzyme misfolding and chronic pancreatitis in mice.
Chronic pancreatitis is a progressive, relapsing inflammatory disorder of the pancreas, which often develops in the background of genetic susceptibility. Recently, loss-of-function mutations in CPA1, which encodes the digestive enzyme carboxypeptidase A1, were described in sporadic early onset cases and in hereditary pancreatitis. Mutation-induced misfolding of CPA1 and associated endoplasmic reticulum (ER) stress was suggested as potential disease mechanism; however, in vivo evidence has been lacking. The objective of the present study was to create a mouse model that recapitulates features of CPA1-associated chronic pancreatitis.
2500. Occult blood in faeces is associated with all-cause and non-colorectal cancer mortality.
作者: Gillian Libby.;Callum G Fraser.;Frank A Carey.;David H Brewster.;Robert J C Steele.
来源: Gut. 2018年67卷12期2116-2123页
An association between detectable faecal haemoglobin (f-Hb) and both the risk of death from colorectal cancer (CRC) and all-cause mortality has been reported. We set out to confirm or refute this observation in a UK population and to explore the association between f-Hb, as indicated by a positive guaiac faecal occult blood test (gFOBT) result, and different causes of death.
|